Dr Reddy's Laboratories Says USFDA Completed GMP Inspection At Our API Manufacturing Facility (CTO-6) In Srikakulam; USFDA Issued Form 483 With Four Observations
Portfolio Pulse from Benzinga Newsdesk
Dr Reddy's Laboratories announced that the USFDA completed a GMP inspection at their API manufacturing facility (CTO-6) in Srikakulam, issuing a Form 483 with four observations.
June 07, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dr Reddy's Laboratories received four observations from the USFDA following a GMP inspection at their API manufacturing facility in Srikakulam. This could indicate potential compliance issues that may need to be addressed.
The issuance of a Form 483 with four observations by the USFDA suggests that there are compliance issues that need to be addressed. This could lead to potential delays or additional costs for Dr Reddy's Laboratories, negatively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100